Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive crawled time : 09:00 save search
PureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in Japan
Published: 2024-02-27 (Crawled : 09:00) - biospace.com/
PTCHF | $2.78 19.97% 560
|
n/a
|
| O: -0.56%
H: 0.0%
C: -0.38%
AKLI | $0.239 2.93% 2.85% 50K
|
|
| O: -3.85%
H: 12.67%
C: 6.92%
japan positive endeavorrx adhd trial results
Grifols announces positive topline phase 3 fibrinogen clinical trial results
Published: 2024-02-14 (Crawled : 09:00) - globenewswire.com
GRFS | News | $6.29 -3.82% -3.97% 1.2M
|
Health Technology
|
| O: 0.48%
H: 3.08%
C: 2.85%
positive topline trial results
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
Published: 2024-01-29 (Crawled : 09:00) - globenewswire.com
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
|
| O: 2.39%
H: 4.67%
C: 1.67%
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: -1.05%
H: 0.41%
C: -0.35%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.11%
H: 0.7%
C: 0.65%
avt03 prolia biosimilar positive results study
Bio-Thera Solutions Announces Positive Results from Phase 3 Study of BAT2206, a Proposed Biosimilar Referencing Stelara®
Published: 2023-11-29 (Crawled : 09:00) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.04%
H: 0.0%
C: 0.0%
bat2206 stelara biosimilar positive solutions results study
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
Published: 2023-11-29 (Crawled : 09:00) - globenewswire.com
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
|
| O: 1.02%
H: 0.0%
C: -5.05%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.04%
H: 0.0%
C: 0.0%
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: 0.73%
H: 0.0%
C: -1.04%
avt05 simponi biosimilar positive results study
Medivir to present clinical data at ASCO-GI with fostrox + Lenvima in HCC and shares positive response from Type D meeting with FDA
Published: 2023-11-13 (Crawled : 09:00) - prnewswire.com
IGMS | $7.2 -2.83% -2.92% 220K
|
Health Technology
|
| O: -0.67%
H: 4.02%
C: 3.79%
fda positive lenvima meeting response
Fortuna receives positive decision from Mexican Court which reinstates the San Jose Mine environmental impact authorization
Published: 2023-10-30 (Crawled : 09:00) - globenewswire.com
FSM | $4.65 3.1% -0.65% 5.3M
|
Non-Energy Minerals
|
| O: 3.46%
H: 0.33%
C: -3.68%
authorization positive impact
European Medicines Agency Committee for Orphan Medicinal Products provides positive opinion on Calliditas' application for setanaxib in Alport syndrome
Published: 2023-10-05 (Crawled : 09:00) - prnewswire.com
CALT | $17.65 -2.4% 4K
|
Health Technology
|
| O: 7.01%
H: 0.0%
C: -4.91%
positive application
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Published: 2023-07-21 (Crawled : 09:00) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.3%
H: 0.0%
C: 0.0%
tepkinly abbvie chmp positive treatment
Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
Published: 2023-07-21 (Crawled : 09:00) - globenewswire.com
GNMSF | $290.38 3.83% 220
|
Health Technology
|
| O: -0.14%
H: 0.82%
C: -1.01%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: -0.22%
H: 0.92%
C: 0.56%
tepkinly abbvie chmp positive treatment
Alnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published: 2023-07-17 (Crawled : 09:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: 0.05%
H: 1.33%
C: 0.38%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: 5.53%
H: 5.23%
C: -2.49%
disease alzheimer’s positive results
Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress
Published: 2023-06-09 (Crawled : 09:00) - biospace.com/
VRTX | News | $394.43 0.24% 0.24% 1.3M
|
Health Technology
|
| O: 0.28%
H: 0.44%
C: 0.18%
CRSP M | $55.04 -1.99% -2.03% 1.8M
|
Health Technology
|
| O: 8.5%
H: 0.52%
C: -9.82%
disease association positive cell trials results
CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Severe Renal Impairment, Including Those on Dialysis
Published: 2023-05-26 (Crawled : 09:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.45%
H: 0.79%
C: -1.17%
covid-19 veklury chmp renal positive dialysis
Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100
Published: 2023-04-17 (Crawled : 09:00) - biospace.com/
RLFTF | $1.43 11.45% 3.8K
|
n/a
|
| O: -2.91%
H: 6.0%
C: -1.0%
rlf-100 positive therapeutics
Zealand Pharma Announces Positive Phase 1 Clinical Results with Amylin Analogue ZP8396
Published: 2023-03-28 (Crawled : 09:00) - globenewswire.com
ZEAL | News | $17.59 1.21% -4.21%
|
Health Technology
| Email alert
Add to watchlist
zp8396 pharma positive results phase 1
Positive topline results from pivotal XTEND-Kids phase 3 study of efanesoctocog alfa in children under 12 years of age with haemophilia A: Swedish Orphan Biovitrum AB
Published: 2023-03-02 (Crawled : 09:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.16%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.76%
H: 1.58%
C: 1.58%
topline children haemophilia positive results study
ViiV Healthcare Announces Positive Data Demonstrating Long-acting Injectable Cabenuva (cabotegravir, rilpivirine) is as Effective as Daily Oral Biktarvy (BIC/FTC/TAF) for the Treatment of HIV-1
Published: 2023-02-23 (Crawled : 09:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.21%
H: 1.09%
C: 0.02%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.04%
H: 0.55%
C: 0.01%
treatment biktarvy positive
Positive Neoadjuvant Libtayo® (cemiplimab) Monotherapy Data in Resectable Cutaneous Squamous Cell Carcinoma Presented at ESMO and Published in NEJM
Published: 2022-09-12 (Crawled : 09:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.78%
H: 0.58%
C: 0.58%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -0.55%
H: 0.43%
C: -1.33%
libtayo positive cell carcinoma
ENHERTU® Significantly Delayed Disease Progression in DESTINY-Breast02 Phase 3 Trial Versus Physician’s Choice of Treatment in Patients with HER2 Positive Metastatic Breast Cancer
Published: 2022-08-15 (Crawled : 09:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.92%
H: 0.22%
C: -0.65%
enhertu treatment disease trial positive cancer her2- her2 metastatic breast cancer
Astellas and Seagen Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer
Published: 2022-07-26 (Crawled : 09:00) - prnewswire.com
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 0.06%
H: 0.71%
C: 0.45%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.75%
H: 4.37%
C: 1.94%
padcev treatment topline positive cancer
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.